Exceptional progress has been made in the past two decades in mapping oncogenes and tumour suppressors, defining a function for these master switches, and identifying novel anti-cancer drug targets. The p53 tumour suppressor is a central component of a DNAdamage-inducible pathway controlled by the ataxia telangiectasia mutated (ATM) and CHK2 protein kinases that have a central role in cancer suppression. One limitation of current human cancer research is the difficulty in developing genetic models that reveal the post-translational regulation of a growth suppressor like CHK2 within the microenvironment of a human tumour. Gaining such insights is important since yeast models and human tissue culture cell lines do not necessarily predict how enzymes like CHK2 are regulated in vivo, and therefore what factors can affect CHK2 tumour suppressor function. Translational cancer research aims to link basic research methodologies and clinical biology by uncovering cancer-specific pathways not revealed by other approaches. This approach is exemplified by two studies in this edition of Oncogene: both use a set of wellcharacterized human cancers with the objective of identifying novel post-translational control of the tumour suppressor CHK2. The authors have revealed two unexpected epigenetic modifications of the CHK2 pathway in vivo: (1) constitutive phosphorylation of CHK2 at its ATM-activated site in the absence of exogenous DNA damage; and (2) the production of hyper-spliced and inactive isoforms of CHK2. These studies highlight the need to develop model systems to understand why CHK2-activating pathways are being triggered or suppressed in different human cancers and whether the splicing machinery can be manipulated to control the activity of CHK2 for therapeutic benefit.
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Chk2 is a tumour suppressor
The Chk2 (CHEK2, hCds1) nuclear serine/threonine kinase is a key component of the highly conserved ataxia telangiectasia mutated (ATM)-dependent DNA damage checkpoint signalling cascade initiated by DNA doublestrand breaks (DSBs) induced by ionizing radiation (IR) and radiomimetic or chemotherapeutic drugs . The ATM damage detector kinase is tethered and activated at DSB sites (Andegeko et al., 2001) , and the damage signal is propagated by ATMmediated phosphorylation of Chk2, principally at the Thr68 activation site (Melchionna et al., 2000; Ward et al., 2001) . Activated Chk2 transmits the damage signal throughout the nucleus and phosphorylates multiple downstream effector proteins . Chk2 effectors include the classic cell cycle phosphatases Cdc25C and Cdc25A (Matsuoka et al., 1998; Falck et al., 2001b) , the breast cancer susceptibility gene product BRCA1 (Zhang et al., 2004a) and transcription factors, including E2F1 (Stevens et al., 2003; Rogoff et al., 2004) and members of the p53 pathway (p53 and p21) (Hirao et al., 2000; Craig et al., 2003) , which function in checkpoint control, DNA repair and apoptosis, and thereby determine cell fate in response to genotoxic insult. Thus, Chk2 activation prevents replication of damaged DNA and reduces the risk of fixing potentially deleterious mutants in a cell population.
The importance of the IR-induced damage-response signalling pathway to organismal survival is underlined by its conservation throughout eukaryotic evolution. Chk2 orthologues in single-cell eukaryotes such as budding yeast (Saccharomyces cerevisiae) and fission yeast (Schizosaccharomyces pombe), rad53 and Cds1, respectively, are integral components of DNA damage response signalling cascades (Sanchez et al., 1996; Rhind and Russell, 2000) . Further, identification of Chk2 homologues in simple metazoa which also have p53 homologues, such as the nematode Caenorhabdatis elegans (Chk-2) and the fruit fly Drosophila melanogaster (MNK), has facilitated genetic analyses of the evolutionary basis of Chk2-p53 interactions (Higashitani et al., 2000; Abdu et al., 2002) . In D. melanogaster, IR-dependent Chk2 activation induces p53-mediated apoptosis and DNA repair, indicating that these are the fundamental roles of the pathway (Brodsky et al., 2004) . The development of gene knockout technology in mice has facilitated an analysis of Chk2 function in a mammalian species. Transgenic mice lacking germline Chk2 are viable, develop normally, and are not intrinsically tumour-prone Takai et al., 2002) . However, these mice are radioresistant, have an increased susceptibility to carcinogen-induced tumorigenesis, and are defective in IR-induced apoptosis and checkpoint control (Hirao et al., 2000; Takai et al., 2002) . Following irradiation, Chk2 null MEFs have reduced p53 stabilization and reduced transactivation of p53 downstream target genes (Hirao et al., 2000; Jack et al., 2002; Takai et al., 2002) . Thus, Chk2 is a key component of a highly conserved damage-response signalling pathway, and p53 is one critical target for Chk2, associated with IR-dependent apoptosis throughout the metazoan lineage.
Loss-of-function Chk2 germline and somatic mutations occur in a range of human tumours, indicating that Chk2 is a major rate-limiting factor for cancer suppression in many tissues . Loss of Chk2-dependent apoptotic signalling will allow spontaneous mutations to propagate in a cell lineage, thereby increasing genome instability. In fact, Chk2 germline mutations have been found in a subset of patients with the cancer-predisposing Li-Fraumeni syndrome (LFS), which retain wild-type p53 (Bell et al., 1999) , indicating that these proteins are components of an overlapping signalling pathway. In LFS patients, loss of heterozygosity at the Chk2 locus leads to sarcomas and breast cancer. In addition, germline Chk2 mutations also contribute to familial breast, colon and prostate cancer syndromes . Preliminary studies indicate that the Chk2 I157T mutations may be a low penetrance allele for breast cancer in the Finnish population (Vahteristo et al., 2002) . Further epidemiological studies may highlight other specific Chk2 mutations as risk factors for cancer in distinct genetic backgrounds.
In contrast, Chk2 somatic mutations occur in broad spectrum diverse tumour types, including sporadic sarcomas and lymphomas, as well as cancers of the breast, colon, bladder, lung, prostate and ovary . Interestingly, the study reported by Staalesen et al in this volume found that, similar to LFS, p53 and Chk2 mutations were mutually exclusive in breast cancers. Sequence analysis of a panel of 53 stage III breast carcinomas found only two cancers with Chk2 mutations, and these were wild type for p53. However, other studies have identified concomitant p53 and Chk2 mutations in a sporadic colorectal cancer-derived cell line (Falck et al., 2001a) and also inactivation of both proteins in breast cancers (Sullivan et al., 2002) , suggesting that Chk2 and p53 proteins have parallel functions. Many different types of cellular insult can activate p53, of which IR is only one and there are many other downstream targets of Chk2 besides p53. Therefore, Chk2 and p53 are components of two distinct networks of signalling pathways, which integrate only under certain conditions. Chk2 mutation should preclude p53 activation only following DSBs, and should not affect the p53 response to other activation signals such as hypoxia or nucleotide depletion. Thus, depending on the specific tumour progression pathway, p53 can still be ratelimiting in the absence of Chk2, and so become a mutational target.
Enzymatic regulation of Chk2
Consensus determinants for classical Chk2 substrates derived from both oriented peptide library and substrate peptide mutagenesis approaches include a hydrophobic residue at the -5 position and arginine at the -3 position (Figure 1a ; O'Neill et al., 2002; Seo et al., 2003) . However, a recently described allosteric mechanism operates in CHK2, whereby kinase docking to a distal site on the p53 core domain alters its conformation and facilitates phosphorylation of p53 and p21 at sites within noncanonical recognition sequences (Craig et al., 2003) . Such allosteric regulation indicates that CHK2 has coevolved with p53 to interact over a wide protein-protein interface, and further provides support for the importance of Chk2 in an element of the p53 stress-response pathway. These data also provide impetus for an investigation of uncharacterized Chk2 regulators and substrates, potentially linking Chk2 to novel signalling pathways.
The Chk2 regulatory amino-terminus comprises an SQ/TQ cluster domain (SCD; residues 19-69), that is the target for upstream phosphatidylinositol-3 kinase (PI-3K)-like kinase (PIKK) activities, and a Figure 1 (a) CHK2 phosphorylation sites. A homology line-up of artificial and natural CHK2 substrates allows for a loose consensus site to be developed. The major phospho-acceptor site highlighted in orange and variable site of homology are in other colors as indicated. The p53 activation domain has two phospho-acceptor sites for CHK1 and CHK2 (the two alignments are shown, with Thr18 or Ser20 being the major phospho-acceptor sites), though the stoichiometry of each preference is undefined. (b) ATM and CHK2 site in the p53 activation domain. The sequence of human p53, fish p53 and human p73 within the p53 activation domain is shown. Phospho-acceptor sites for CHK2 are in red and ATM in green. The Thr18 phospho-acceptor site is one of the most highly conserved in p53, while the Ser20 phospho-acceptor site one of the least conserved. P300 binding is stabilized by any of the three phosphorylations, while MDM2 binding is attenuated only by the Thr18 phosphorylation phosphopeptide-binding Forkhead-associated (FHA) module (residues 113-175). The carboxy-terminal catalytic domain (220-486) is related to the Ca 2 þ /calmodulin-dependent protein kinase (CaMK) family. Although the Chk2 kinase domain has been recalcitrant to crystallization, the structures of kinase domains from related kinases such as Chk1 kinase and the deathassociated protein kinase (DAPK1) have been solved Tereshko et al., 2001) , and some insight into the structure of the Chk2 kinase domain can be approximated by mapping the positions of the conserved amino acids onto the structures of these related kinases. However, to understand the effects of regulatory factors and gene mutation on Chk2 function, it will be essential to define the precise structure of fulllength Chk2 monomers and homodimers.
As a first step in the delineation of the damage response pathway, genetic studies revealed that IRinduced Chk2 kinase activity is reduced in ATMdeficient cells (Matsuoka et al., 1998; Hirao et al., 2002) . Mutation analysis of the SCD region identified Thr68 as the major ATM phosphorylation site on Chk2 in vitro and in vivo Melchionna et al., 2000) , and mutation of this residue significantly reduces IR-stimulated Chk2 kinase activity (Melchionna et al., 2000) . Interestingly, ATM-independent Chk2 activation has also been reported, suggesting that other PIKKs can replace the function of ATM in Chk2 activation under some conditions (Theard et al., 2001; Hirao et al., 2002) . Although the structure of the SQ/ TQ-rich domain has not yet been solved, and is likely to be conformationally flexible, X-ray crystallography has elucidated the structure of the FHA protein interaction module. Similar to homologous FHA modules defined in other signalling proteins, the Chk2 FHA domain consists of an 11-stranded b-sandwich that forms a phospho-threonine (phosphoThr)-binding module . Random mutagenesis was used to identify an optimal binding motif, HFD(phospho)-TYLI, which has a dissociation constant (K d ) of 0.9 mM. The aspartate residue at the À1 position and the isoleucine at the þ 3 position have been identified as critical binding residues. Interestingly, a related peptide based on the amino acids surrounding phosphoThr68 within the Chk2 SQ/TQ-rich domain bound to the isolated Chk2 FHA domain, although with a reduced affinity (K d E30 mM) . Although the sequence ETVSTQELY has a conserved hydrophobic residue at the þ 3 position, there is a hydrophobic serine at the -1 position, which may account for the reduced affinity. However, IR-induced Thr68 phosphorylation forms a specific ligand for the FHA domain of another Chk2 molecule, which provides a mechanism for Chk2 homodimerization, a critical step in the physiological activation of Chk2 in response to DSBs (Xu et al., 2002) . Following Chk2 homodimerization, intermolecular transphosphorylation at Thr383 and Thr387 within the activation loop leads to full activation of Chk2 (Lee and Chung, 2001; Ahn et al., 2002) . In the final step of Chk2 activation, the FHA domain itself becomes phosphorylated, thereby reducing the affinity of the intermolecular interactions, and releasing active Chk2 monomers (Ahn et al., 2002) .
CHK2 and p53 phosphorylation are regulated by two overlapping ATM-dependent pathways
The cellular response to DSBs is regulated primarily through a kinase cascade initiated by ATM that leads to phosphorylation of a number of its downstream effector targets such as p53, CHK2, SMC1, FANCD2 and H2AX at SQ or TQ consensus sites within clustered motifs. Although it is not precisely known how ATM kinase is activated by DNA damage, growing evidence points to a post-translational activation mechanism. One initiating IR-induced phosphorylation site was mapped to the C-terminal region that plays a role in dissociating latent oligomers of ATM into active monomers (Bakkenist and Kastan, 2003) . ATM is also activated towards its substrates by a multi-protein complex that is composed of three proteins including Mre11, Rad50 and Nbs1 (Lee and Paull, 2004) . Mutation of components of the MRN complex in diseases include ATLD (AT-like disease involving mutations in Mre11) and Nijmegen break syndrome (mutations in Nbs) results in radiation sensitivity, chromosomal instability, radio-resistant DNA synthesis, immunodeficiency and cancer (Carney et al., 1998) . Such phenotypes are similar to those seen in patients with AT, and are consistent with the MRN protein complex being part of the same signalling pathway as ATM. How ATM activity is stimulated by the MRN complex is not clear, but presumably involves an allosteric component as ATM concentration in vitro affects the stimulation of its activity by MRN and mutant components of the MRN complex fail to stimulate ATM (Lee and Paull, 2004) .
One peculiarity of the ATM-CHK2-p53 activation pathway is that both ATM and CHK2 target adjacent residues in the transactivation domain of p53, at serine-15 (Ser15) and serine-20 (Ser20), respectively (Figure 1b) . The effects of ATM phosphorylation of p53 at Ser15 and CHK2 phosphorylation at Ser20 are not to reduce MDM2 binding, but to stabilize p300 binding (Dornan and Hupp, 2001 ). This stabilization leads to DNAdependent acetylation of p53 and enhanced gene expression of p53-targeted promoters (Dornan et al., 2003) . It is not clear what the stoichiometry of the modification is in vivo or whether one activation domain has two phosphorylation sites within one arm of the tetramer. Further, CHK2 and the related CHK1 can be activated allosterically towards the adjacent threonine-18 (Thr18) and Ser20 sites, and supershift analysis of the phospho-peptide product suggests that CHK2 and CHK1 can modify the two phosphoacceptor sites within the same activation peptide (Craig et al., 2003) . It is not clear why two or three phosphorylation events are induced in the p53 activation domain, but it may be to maximize p300:p53 complex stability and induce a more potent p53 response. Regardless, what is clear is that two distinct modifying pathways are involved in driving ATM targeting of either CHK2 or p53 in response to DNA damage.
ATM phosphorylation of CHK2 at Thr68 is stimulated by the trimeric MRN complex composed of Mre11, Rad50, and Nsb1. By contrast, p53 phosphorylaiton by ATM in vitro can be stimulated by Mre11 and Rad50 alone and is Nsb1-independent in vitro ( Lee and Paull, 2004) . This specificity in the MRN or MR complex being involved in mediating ATM phosphorylation of CHK2 and p53, respectively, suggests that two distinct pathways mediate ATM targeting of p53 and CHK2 (Figure 2 ). This has also been supported by recent data describing a novel E2F1-mediated CHK2 activation pathway. E2F1-mediated induction of p53-dependent apoptosis coincides with enhanced Ser15 phosphorylation of p53, suggesting that ATM is being activated towards p53. In support of this, the E2F1-mediated induction of Ser15 phosphorylation is attenuated in AT cells, but remains largely intact in cells from patients with NBS (Rogoff et al., 2004) . However, CHK2 phosphorylation at Thr68 and CHK2-mediated phosphorylation of p53 at Ser20 are attenuated in cells from patients with AT or NBS (Rogoff et al., 2004) . Together, these data are again consistent with in vitro reconstitution studies showing that the trimeric MRN complex is required for CHK2 activation by ATM, while MR alone is sufficient for ATM activation of p53 in an NBS1-independent manner (Figure 2) . Two more recent studies show the converse, that there are factors that can control p53 phosphorylation with little effects on CHK2 modification.
The tumour suppressor BRCA1 is mutated in a large proportion of familial breast or ovarian cancers (Miki et al., 1994) and is phosphorylated by ATM (as well as Chk2), suggesting a link between ATM and BRCA1-mediated tumour suppression. Although the function of BRCA1 is not precisely known, it does exist in a large multi-protein complex, a genome surveillance complex, containing other ATM targets including NBS1, BLM and SMC1 (Wang et al., 2000) . BRCA1 is also found in complex with a protein called BARD1. siRNA directed towards the BRCA1/BARD1 complex attenuates p53 phosphorylation at Ser15, with little effects on CHK2 phosphorylation (Fabbro et al., 2004) . Further, the estrogen receptor-inducible gene product, Anterior Gradient-2, can silence p53-mediated transactivation and attenuate Ser15 of p53 without affecting CHK2 phosphorylation (Pohler et al., 2004) . Together, these data provide evidence for a model whereby Nbs1 is a specificity factor that directs ATM-mediated phosphorylation of CHK2, whereas BRCA1/BARD1 and AG-2 are factors that modulate selected ATM-dependent phosphorylation of p53 (Figure 2) .
With these mechanistic studies on the ATM-CHK2-p53 pathway providing a background framework, a study on CHK2 phosphorylation status in human cancers defines a clinical end point that can provide a justification for further dissection of the ATM-CHK2-p53 pathway in cancer progression models. In this volume, Bartkova et al. report that constitutive phosphorylation of Chk2 at its ATM phosphorylation site (Thr68) is very common in untreated advanced primary urinary bladder cancers. The group previously used carefully characterized phospho-specific antibodies to develop an immunochemical detection method for identifying Chk2 Thr68 site-specific phosphorylation in fixed tumour samples. Using this technique to screen a panel of 58 grade T2-T4 bladder cancers, they found that a large subgroup of the tumours (up to 90%) stained positive for Thr68 phosphorylation of Chk2, indicating that in many cases Chk2 is receiving a constitutive activation signal, presumably by activated ATM. Similar aberrant Chk2 phosphorylation has previously been reported for untreated primary breast, colon and lung cancers, although in much smaller sample subsets (DiTullio et al., 2002 ). Further, a high level of Thr18 and Ser20 phosphorylation of p53 protein was previously detected in a panel of primary breast cancers (Craig et al., 1999) ; since these are the CHK1/2 phosphorylation sites in p53, these data suggest that CHK2/1 activity is also widely activated in breast cancers.
Bartkova et al. speculate that a combination of genomic instability and telomere erosion in advanced tumours could be the damaging signals detected by ATM, leading to Chk2 Thr68 hyperphosphorylation and constitutive Chk2 activation in these tumours, and Figure 2 The ATM activation cascade targets CHK2 and p53 using overlapping modifiers. ATM activation by DNA damage results in ATM(R)-dependent modification of both p53 and CHK2. The mechanism of activation involves common and distinct cofactors. CHK2 modification at Thr68 is dependent upon the MRN complex (Lee and Paull, 2004 ) and this in turn can lead to phosphorylation of p53 in the transactivation domain at Ser20 in a CHK2-dependent manner (Rogoff et al., 2004) . Thus, Ser20 phosphorylation of p53 is Nbs1-dependent. However, p53 modification at Ser15 by ATM is independent of Nbs1 ( Lee and Paull, 2004; Rogoff et al., 2004) , but requires BRCA1/BARD complexes, which in turn are not required for CHK2 phosphorylation by ATM (Fabbro et al., 2004) . Modifiers of p53 or CHK2 phosphorylation at the ATM(R) sites include E2F1, which can lead to Nbs1-dependent phosphorylation of CHK2 at Thr68 and p53 phosphorylation at Ser20 (Rogoff et al., 2004) or the breast cancer antigen AG-2, which can attenuate Ser15 phosphorylation of p53 in response to DNA damage (Pohler et al., 2004) that under these conditions p53 and/or Chk2 become likely mutational targets for cancer progression. However, given that E2F1 can also induce ATM and CHK2-mediated phosphorylation of p53 (Rogoff et al., 2004) , these data also suggest that the so-called 'oncogene' stimulation may be a trigger for ATM activation and that intrinsic pathways may trigger activation of the p53 pathway as a way to promote tumour suppression. In fact, a recent study using a transgenic animal with an ARF-GFP-promoter fusion demonstrated that the ARF promoter is being fired in developing cancers in vivo (Zindy et al., 2004) and thus providing selective pressures for mutating these activation pathways as tumour cells evolve. Further work will be required to determine whether such intrinsic tumour suppression is triggered by a combination of cytokines, factors such as E2F, genome instability and endogenous telomere erosion. Regardless, the fact that 90% of these bladder cancers have modified the ATM site on CHK2 suggests that, if MRN is activating ATM, these three proteins are not silenced in vivo. By contrast, cancers without high levels of CHK2 phosphorylation may have silenced ATM sensing pathway by either acquiring mutations in ATM, disruption of the MRN complex, silencing E2F1, or reducing telomere erosion rates.
Independent studies using cancer material also suggest that two different natural histories occur in breast cancer development with respect to ATM activation. In an analysis of a large panel of breast cancers examining p53 mutation status versus ATM-site phosphorylation of p53 at Ser15, it was found that very high levels of Ser15 phosphorylation (i.e. ATM 'activation') were detected in cancers with mutant p53, whereas in cancer with wild-type p53 relatively little Ser15 phosphorylation can be detected (Borek Vojtesek, personal communication) . These data suggest that in cancers that have evolved p53 mutations, the ATM 'sensing' pathway is intact, but the defect in p53 via mutation prevents firing of the tumour suppressor. In contrast, cancers with wild-type p53 may have attenuated the upstream ATM signalling pathway, possibly by AG-2 expression (a common occurrence in breast cancers) or by reduction in the ATM stimulators Mre11, RAD50, or BRCA1/BARD. Either way, these clinical studies provide an exciting validation of basic research and will hopefully inspire follow-up work to examine the precise signalling pathway that is activated in vivo.
A novel mechanism for CHK2 silencing in cancers Until recently, genetic changes have been considered to be almost entirely responsible for cancer-associated Chk2 inactivation. However, it is becoming increasingly apparent that epigenetic factors can regulate Chk2 function. A large number of tumour-derived mutations have partly defined the mechanisms of Chk2 epigenetic silencing. Most common are missense mutations within the regulatory domains, and frameshift mutations leading to truncations within the catalytic domain . Biochemical analysis of the most common Chk2 mutants revealed that Chk2 can be inactivated by several distinct mechanisms. For example, the common frameshift C1100del and T1422del mutations encode premature stop codons within the catalytic domain, and the resulting truncated mutant proteins are both inactive and unstable . In contrast, the common missense mutations within the FHA domain, I157T and R145W, retain the entire kinase domain, but differ in their IR-induced activation potentials. The R145W mutant is defective in Thr68 phosphorylation, and has reduced kinase activity (towards the Cdc25C substrate), whereas the I157T mutant undergoes Thr68 phosphorylation and is fully active towards Cdc25C . Further, the R145W mutant is unstable, whereas the I157T mutant has a stability similar to wild-type Chk2. Significantly, and unlike wild-type Chk2, neither of these mutants can form a complex with p53 and both are defective in IR-induced p53 phosphorylation (Falck et al., 2001a) . Since the I157T mutant is active towards CDC25, future studies should determine whether the activity of the I157T mutant is compromised towards p53 (at least), since it is possible that some subset of CHK2 mutants will retain docking-independent modification of CDC25, but be defective in the allosteric docking that mediates p53 phosphorylation.
Strikingly, the novel breast cancer-derived Chk2 frameshift mutant insA1368 identified in the report by Staalesen et al in this volume encodes a premature stop codon within the kinase domain, resulting in expression of a stable protein that is mislocalized to the cytoplasm. Cytoplasmic sequestration can inactivate Chk2 by preventing activation by nuclear ATM signals, or phosphorylation of downstream nuclear targets. As the breast cancer sample containing the novel mutation retained a wild-type Chk2 allele and presumably expresses some wild-type Chk2 protein, it is probable that the novel mutant protein sequesters the remaining wild-type Chk2 to the cytoplasm, presumably by heterodimerization. Interestingly, the breast cancer expressing the insA1368 mutant was found to be doxorubicin resistant, a characteristic normally associated with mutated p53 in these tumours. Thus, cytoplasmic localization may be a novel marker for breast cancers that are drug resistant. In summary, identification of this novel Chk2 mutant expands the repertoire of Chk2 inactivation mechanisms to include loss of kinase activity, protein instability or mislocalization, and loss of substrate recognition.
Other epigenetic mechanisms of Chk2 silencing are now beginning to be delineated. Promoter methylation is commonly associated with inactivation of the tumour suppressors such as p16 INK4 (Rocco and Sidransky, 2001 ) and DAPK-1 Tyler et al., 2003) . Recent studies indicate that methylation of the Chk2 promoter occurs in non-small-cell lung carcinoma (Zhang et al., 2004b) . The discovery of a more direct epigenetic mechanism of Chk2 silencing provides an opportunity to include DNA-methylase inhibitors in combined drug therapies of some cancers. In this volume, Staalesen et al. identify an enhanced level of alternative splicing of the CHK2 transcript as a novel mechanism for Chk2 inactivation in advanced breast cancers. Approximately 90 alternatively spliced Chk2 mRNA isoforms were identified in a panel of 53 stage III breast carcinomas, in addition to normal cells. Intriguingly, some of these newly identified splice variants in normal cells contain intronic sequences that could be novel exons that are not included in wild-type Chk2 mRNA. Alternatively spliced Chk2 isoforms were also identified in normal breast tissue, occurring at a rate of approximately four splice variants per biopsy. However, on average, breast cancers expressed 15 variants/tumour, indicating that the incidence of alternative splicing increases with increasing cellular dysregulation. Further, for patients in whom matched normal and tumour tissue was available, all of the Chk2 variants found in normal tissue were also present in the tumour samples, along with extra tumour-specific variants.
Selected Chk2 splice variants were cloned and subjected to functional analysis in vitro. The majority of splice variants lack the entire or part of the kinase domain, and could inactivate coexpressed wild-type Chk2 protein. Only two splice variants retained the kinase domain; the del2-3 isoform lacking part of the FHA domain exhibited 60% kinase activity, while the insX isoform, containing an aberrant insert N-terminal of the FHA domain, had severely reduced kinase activity. All of the splice variants localized to the nucleus, with the exception of the iso2 variant, which was pancellular. Only the insZ splice variant, consisting of the regulatory domain only, was expressed at increased levels over wild type in vivo and therefore could potentially function as a dominant-negative transcript to inactivate wild-type Chk2 by heterodimerization, leading to the formation of an inactive complex.
As Chk2 signalling pathways have become more complex throughout evolution, it will be of interest to determine whether alternatively spliced Chk2 isoforms exist in organisms such as C. elegans and D. melanogaster. Identification of such alternatively spliced forms in more tractable organisms would help to elucidate the function and/or evolution of the splicing diversity, as, presumably, CHK2 splicing has some selective advantage to normal cells which would be exploited or dysregulated in tumour cells. For example, if CHK2 hypersplicing is relatively specific to vertebrates or mammals, then this would suggest that a CHK2-shuffling mechanism may have evolved later in evolution as a buffer to help normal cells prevent CHK2 being neutralized by a viral oncogene, or as a post-translational way to inactivate CHK2 kinase without CHK2 protein degradation. The maintenance of this mechanism in other species would suggest that selective pressures still utilize this control of CHK2. Further, cancer cells may exploit this finely evolved control by producing enhanced spliced CHK2 isoforms that function as dominant-negative cellular oncogenes. If CHK2 is produced as a spliced, dominant-negative oncogenic derivative in some cancers, then the treatment of 'CHK2-positive' cancers with CHK2 kinase inhibitors would not give the desired effect as most of the enzyme would be inactive. Thus, rational treatment of cancers with CHK2 inhibitors based on immunochemical positivity would be misleading without a more refined analysis of CHK2 protein isoforms in the cancers. In addition, expression of the insZ 'oncogenic' variant in tumours that were nonresponsive to primary doxorubicin therapy suggests its use both as a prognostic marker, and for the development of rational therapeutic strategies in tumours with wild-type Chk2. Future research should be developed to understand how the oncogenic alternatively spliced CHK2 molecules function so that new strategies can be developed to block the putative dominant-negative function of CHK2 variants.
Aberrant hyper-splicing of mdm2 mRNA occurs in many tumour types (Bartel et al., 2002 (Bartel et al., , 2004 . Similar to Chk2, some Mdm2 splice variants are dominant negative over wild-type Mdm2 (Evans et al., 2001) , while others have enhanced oncogenicity and are associated with p53-independent tumorigenesis (Fridman et al., 2003; Steinman et al., 2004) . Further, lactate dehydrogenase C (LDHC) is alternatively spliced in a tumour-specific manner, and most splice variants have reduced catalytic function (Koslowski et al., 2002) . Although the mechanism regulating the enhanced processing of alternatively spliced transcripts in tumours is unknown, these data suggest that, as cells lose their normal regulation, hyper-splicing may become a major epigenetic mechanism for facilitating tumour progression in the CHK2-p53 pathway. Studies in human cancers, which comprehensively analyse CHK2 or p53 phosphorylation, p53 or CHK2 alternative splicing, and BRCA1 or AG-2 modifier gene expression, may give rise to a natural history describing specific steps that can be achieved to silence the p53-CHK2 tumour suppressor pathway.
Summary
Loss of Chk2 signalling in cancer cells by gene mutation mechanisms inhibits DSB-induced apoptosis, resulting in a lack of response to chemotherapy and radiotherapy. Understanding both the genetic and epigenetic mechanisms of Chk2 inactivation will help to identify Chk2 inhibitors as drug targets for combinatorial chemotherapy, whereby tumours with inactive Chk2 signalling could be sensitized to apoptosis. For this strategy to be successful, a full understanding of the various mechanisms for Chk2 inactivation in tumours must be available. In contrast, however, it was recently reported that loss of functional Chk2 causes cancer cells to undergo mitotic catastrophe leading to apoptosis, either in response to nonsynchronized cell fusion or to chemically induced DSBs (Castedo et al., 2004) . These data indicate that for some tumour environments Chk2 inhibitors could be appropriate constituents of combined therapies to sensitize cancers to chemotherapy-induced apoptosis. It is clear that the specific cancer environment drives the mechanism of Chk2 inactivation on apoptotic signalling. Further studies to improve our understanding of the function and regulation of human Chk2 signalling network in vivo are therefore essential to develop Chk2 modulators as novel components of anticancer therapies.
